公开(公告)号：US20240327491A1

公开(公告)日：2024-10-03

申请号：US18576468

申请日：2022-07-11

申请人： Ludwig Institute for Cancer Research Ltd

发明人： George Coukos ,  Alexandre Harari ,  Sara Bobisse ,  Marion Arnaud ,  Michal Bassani-Sternberg

IPC分类号： C07K14/725 ,  A61K39/00 ,  A61P35/00 ,  C12N5/0783 ,  G01N33/574

CPC分类号： C07K14/7051 ,  A61K39/4611 ,  A61K39/4632 ,  A61K39/464401 ,  A61P35/00 ,  C12N5/0636 ,  G01N33/57484 ,  A61K2239/31 ,  C12N2510/00 ,  G01N2333/7051

摘要： This disclosure describes novel T cell receptors (TCRs) specific for tumor-associated antigens (TAAs) and methods of use thereof. The disclosed TCRs and methods of use expand the applications of adoptive cell therapy and TCR-based cellular immunotherapies.

公开(公告)号：US20240293454A1

公开(公告)日：2024-09-05

申请号：US18016293

申请日：2021-06-02

申请人： GUANGZHOU FINELMMUNE BIOTECHNOLOGY CO., LTD.

发明人： Haiping LIU ,  Xiang LI ,  You LI ,  Chaochao BIAN

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C07K14/52 ,  C07K14/705 ,  C12N5/0783 ,  C12N15/86 ,  C12Q1/6841 ,  C12Q1/6869 ,  C12Q1/6886 ,  G01N33/50

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4632 ,  A61K39/464411 ,  A61K39/464417 ,  A61K39/464442 ,  A61P35/00 ,  C07K14/47 ,  C07K14/521 ,  C07K14/70521 ,  C07K14/70575 ,  C07K14/70596 ,  C12N5/0636 ,  C12N15/86 ,  C12Q1/6841 ,  C12Q1/6869 ,  C12Q1/6886 ,  G01N33/505 ,  C12N2740/15043 ,  C12Q2600/158 ,  G01N2333/7051

摘要： The present disclosure provides a TCR-T cell for tumor-killing, wherein the TCR-T cell is a T cell carrying a TCR that recognizes a tumor antigen, and the TCR in the TCR-T cell is derived from any one or more of the following T cells: 1) a CD4 T cell expressing one or more of TNFRSF18, CXCL13, TNFRSF4, TNFSF8, ENTPD1, ACP5, LAYN, TNFRSF9, CTLA4, CD200 and TIGIT genes in the tumor; and 2) a CD8 T cell expressing one or more of TNFRSF18, CXCL13, CXCR6, GALNT2, ENTPD1, ACP5, HAVCR2, LAYN, TNFRSF9, CTLA4 and CD109 genes in the tumor. The TCR-T cell according to the present disclosure can be effectively applied to the treatment of a tumor, especially in an immunotherapy.

公开(公告)号：US12018064B2

公开(公告)日：2024-06-25

申请号：US17396305

申请日：2021-08-06

申请人： Immatics Biotechnologies GmbH

发明人： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Lea Stevermann

IPC分类号： A61K38/00 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569

CPC分类号： C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12006349B2

公开(公告)日：2024-06-11

申请号：US17396323

申请日：2021-08-06

申请人： Immatics Biotechnologies GmbH

发明人： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Lea Stevermann

IPC分类号： A61K38/00 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569

CPC分类号： C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230417743A1

公开(公告)日：2023-12-28

申请号：US18241668

申请日：2023-09-01

申请人： CytoSed, Inc.

发明人： Warren L. Dinges

IPC分类号： G01N33/539 ,  G01N33/569 ,  C07K16/00 ,  G01N33/537

CPC分类号： G01N33/539 ,  G01N33/56966 ,  G01N33/56988 ,  C07K16/00 ,  G01N33/56972 ,  G01N33/5375 ,  G01N2333/7051

摘要： The present disclosure is directed to antibody-linked immuno-sedimentation agent, the antibody being linked to a sedimentation agent by a non-antigen binding region of the antibody, and a method of isolating a target from a sample using the antibody-linked immuno-sedimentation agent. The methods involve forming a mixture including a sample with an antibody linked immuno-sedimentation agent and red blood cells under conditions sufficient to form red blood cell rouleaux and allow antibody-antigen binding.

公开(公告)号：US20230408524A1

公开(公告)日：2023-12-21

申请号：US18209814

申请日：2023-06-14

申请人： Synarc Research Laboratory (Beijing) Ltd. ,  HEBEI YANDA LUDAOPEI HOSPITAL

发明人： Hui Wang ,  Man Chen ,  Aixian Wang ,  Meiwei Gong ,  Xueying Wu ,  Junyi Zhen ,  Qing Du ,  Ya Guo

IPC分类号： G01N33/574

CPC分类号： G01N33/57492 ,  G01N2333/70589 ,  G01N2333/70596 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70514

摘要： The present invention provides a reagent composition for detection of a non-hematopoietic tumor and use thereof. Said reagent composition includes three sets of antibodies, with the first set of antibodies including an anti-CD9 antibody, an anti-GD2 antibody, an anti-CD3 antibody, an anti-CD4 antibody, an anti-CD56 antibody, an anti-CD36 antibody, an anti-CD81, and an anti-CD45 antibody; the second set of antibodies including an anti-HLA-ABC antibody, an anti-CD38 antibody, an anti-CD19 antibody, an anti-CD56 antibody, an anti-CD36 antibody, an anti-CD7 antibody, and an anti-CD45 antibody; the third set of antibodies including anti-cytoplasmic cytokeratin antibodies; wherein the first set of antibodies and the second set of antibodies are respectively used for samples in separate tubes, and the third set of antibodies is used for the sample in the same tube as the second set of antibodies. The reagent composition of the present invention can be applied for flow cytometry screening, diagnosis and/or follow-up detection of a non-hematopoietic tumor.

公开(公告)号：US11820823B2

公开(公告)日：2023-11-21

申请号：US16759680

申请日：2018-10-26

申请人： Kite Pharma, Inc.

发明人： Stephanie Astrow ,  Stuart Sievers ,  Jed Wiltzius

IPC分类号： C07K16/28 ,  G01N1/30 ,  G01N33/569

CPC分类号： C07K16/2809 ,  G01N1/30 ,  G01N33/56972 ,  G01N2001/305 ,  G01N2333/7051

摘要： Isolated antigen binding molecules that specifically bind to a polypeptide comprising the alpha chain of the constant region of a T cell receptor (TCR) are provided. The antigen binding molecules may be used in the methods provided herein.

公开(公告)号：US20190219577A1

公开(公告)日：2019-07-18

申请号：US16337003

申请日：2017-09-30

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITÉ DE MONTPELLIER

发明人： Monsef BENKIRANE ,  Gael PETITJEAN ,  Benjamin DESCOURS

IPC分类号： G01N33/569 ,  C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC分类号： G01N33/56988 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2809 ,  C07K16/283 ,  C07K2317/31 ,  C12N5/0636 ,  C12N2501/2302 ,  C12N2501/515 ,  C12N2501/53 ,  G01N2333/7051 ,  G01N2333/70535

摘要： The use of differentiation marker CD89 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD89 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD89 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody for treatment.

公开(公告)号：US20190178886A1

公开(公告)日：2019-06-13

申请号：US16201689

申请日：2018-11-27

申请人： Roche Molecular Systems, Inc.

发明人： Jan Berka ,  Sri Paladugu

IPC分类号： G01N33/566 ,  C12N15/10

CPC分类号： G01N33/566 ,  C12N15/1037 ,  C12N15/1065 ,  C12N15/1096 ,  C12Q1/6809 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/6878 ,  G01N2333/7051 ,  C12Q2563/179

摘要： Methods, compositions, and reaction mixtures are provided for identifying a T cell receptor (TCR) and an epitope peptide that specifically binds the TCR. Methods, compositions, and reaction mixtures are also provided for identifying a plurality of T cell receptors and corresponding epitope peptides that specifically bind the T cell receptors. In some cases, the plurality of T cell receptors and corresponding epitope peptides can be identified in a highly parallel manner.

公开(公告)号：US20180372744A1

公开(公告)日：2018-12-27

申请号：US15967627

申请日：2018-05-01

申请人： CASE WESTERN RESERVE UNIVERSITY

发明人： Mark R. Chance

IPC分类号： G01N33/569 ,  G01N33/68

CPC分类号： G01N33/56988 ,  A61K31/496 ,  A61P9/00 ,  A61P31/12 ,  A61P31/18 ,  C07K14/47 ,  G01N33/50 ,  G01N33/6893 ,  G01N33/92 ,  G01N2333/16 ,  G01N2333/7051 ,  G01N2333/70514 ,  G01N2333/70596 ,  G01N2405/04 ,  G01N2800/26 ,  G01N2800/32 ,  G01N2800/50

摘要： A method for determining the risk of cardiovascular disease in a subject having a chronic viral infection includes determining a level of determining a level of at least one lysophophatidic acid (LPA) subtype in the subject, wherein the LPA subtype is selected from the group consisting of LPA 16:0, 18:1, 18:2, and 20:4 and comparing the determined level of the at least one LPA to a control level, wherein an increased level of at least one LPA subtype is indicative of the subject having an increased risk of cardiovascular disease associated with the chronic viral infection.